Co-Authors
This is a "connection" page, showing publications co-authored by Houssein Ayoub and Riyazuddin Shaik.
Connection Strength
0.764
-
Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innov. 2021 Apr; 7(2):327-336.
Score: 0.234
-
Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J Glob Health. 2021 Jan 16; 11:05005.
Score: 0.231
-
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021 10 11; 28(7).
Score: 0.061
-
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clin Infect Dis. 2021 10 05; 73(7):e1830-e1840.
Score: 0.061
-
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 09; 27(9):1614-1621.
Score: 0.060
-
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis. 2021 05; 27(5):1343-1352.
Score: 0.059
-
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May; 35:100861.
Score: 0.059